MPD-RC 112: Frontline Peginterferon α-2a vs Hydroxyurea in High-Risk Polycythemia Vera and Essential Thrombocythemia

December 3-6, 2016; San Diego, California
Results from interim analysis of phase III trial found no difference in CR at 12 months between therapies, and grade ≥ 3 AEs occurred more frequently in patients receiving pegIFN α-2a.
Format: Microsoft PowerPoint (.ppt)
File Size: 633 KB
Released: December 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021

Danielle Friedman, MD, on adipose dysfunction, insulinopenia, obesity, and diabetes after irradiation in cancer survivors

Danielle N. Friedman, MD, MS Released: April 22, 2021

On-demand Clinical Care Options (CCO) webcast with experts’ review of data informing optimal management of relapsed/refractory myeloma

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 31, 2021 Expired: March 30, 2022

From Clinical Care Options (CCO), read an expert commentary on how to safely provide CAR T-cell therapy during the COVID-19 pandemic

person default Caron A. Jacobson, MD Released: March 31, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue